Evidence map›Paper›PMID 36944680›Full record

ArticleNature communications2023

Cellular mechanisms of heterogeneity in NF2-mutant schwannoma.

Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A Wright, Elizabeth A Flynn, Shannon L Stott, Marco Giovannini, Andrea I McClatchey

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Molecular therapy. Nucleic acids · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christine Chiasson-MacKenzieMassachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA.ORCID 0000-0002-4820-9765
Jeremie VitteDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0002-2567-7988
Ching-Hui LiuMassachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA.
Emily A WrightMassachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA.
Elizabeth A FlynnMassachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA.
Shannon L StottMassachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA.
Marco GiovanniniDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0001-5183-8506
Andrea I McClatcheyMassachusetts General Hospital Cancer Center, Harvard Medical School, 149 13th Street, Charlestown, MA, 02129, USA. mcclatch@helix.mgh.harvard.edu.ORCID 0000-0002-6150-3619
Harvard University · USUniversity of California, Los Angeles · US

Funding

Benchmarking the Sensitivity and Specificity of the Herringbone Microfluidic Device for Rare Particle CaptureR01CA226871 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHED, BRIAN VALA, STOTT, SHANNON L · 2018 to 2023
$2.3M
Multiphoton Microscope for Deep Tissue ImagingS10OD025017 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENTOLILA, LAURENT A. · 2018 to 2018
$599k
NCI NIH HHS R01 CA226871NIH HHS S10 OD025017
6 · The paper itself

Abstract

Schwannomas are common sporadic tumors and hallmarks of familial neurofibromatosis type 2 (NF2) that develop predominantly on cranial and spinal nerves. Virtually all schwannomas result from inactivation of the NF2 tumor suppressor gene with few, if any, cooperating mutations. Despite their genetic uniformity schwannomas exhibit remarkable clinical and therapeutic heterogeneity, which has impeded successful treatment. How heterogeneity develops in NF2-mutant schwannomas is unknown. We have found that loss of the membrane:cytoskeleton-associated NF2 tumor suppressor, merlin, yields unstable intrinsic polarity and enables Nf2

Indexed as

NeurilemmomaNeurofibromatosis 2AnimalsGenes, Tumor SuppressorHumansMiceMutationNeurofibromin 2Schwann CellsNeurofibromin 2

Identifiers

PMID36944680
PMCPMC10030849
OpenAlexW4328129271

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read85
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.